


DOCKET NO.: CEPH-2456/CP184B

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Richard W. Scott

Confirmation No.: Not Yet Assigned

Application No.: 10/797,289

Group Art Unit: Not Yet Assigned

Filing Date: March 10, 2004

Examiner: Not Yet Assigned

For: **GENE-TARGETED NON-HUMAN MAMMAL WITH HUMAN FAD
PRESENILIN MUTATION AND GENERATIONAL OFFSPRING**

DATE OF DEPOSIT: *April 13, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☒ In view of the voluminous nature of references 14 and 23, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references **1-42, 116 and 122** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/041,185**, filed **March 10, 1998**; copies of references **43-114 and 117-121** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/621,897**, filed **July 20, 2000**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ The English language equivalent of WO 99/34670, which is not in the English language, is EP – 1 044 605 A1 both listed on the Form PTO-1449.

Date: April 13, 2004


Felicity E. Groth
Registration No. 47,042

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CEPH-2456/CP184B	Application No. 10/797,289
		Applicant Richard W. Scott	
		Filing Date March 10, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Askew et al., "Site-Directed Point Mutations in Embryonic Stem Cells: a Gene-Targeting Tag-and-Exchange Strategy," <i>Mol. Cell Biol.</i> , 1993 , 13(7), 4115-4124	
	2	Borchelt et al., "Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate A β 1-42/1-40 Ratio In Vitro and In Vivo," <i>Neuron</i> , 1996 , 17, 1005-1013	
	3	Capecchi, M.R., "The New Mouse Genetics: Altering the Genome by Gene Targeting," <i>Trends Genet.</i> , 1989 , 5(3), 70-76	
	4	Cataldo et al., "Gene Expression and Cellular Content of Cathepsin D in Alzheimer's Disease Brain: Evidence for Early Up-Regulation of the Endosomal-Lysosomal System," <i>Neuron</i> , 1995 , 14, 671-680	
	5	Church et al., "Genomic sequencing," <i>Proc. Natl. Acad. Sci.</i> , 1984 , 81, 1991-1995	
	6	Clark et al., "The structure of the presenilin 1 (<i>S182</i>) gene and identification of six novel mutations in early onset AD families," <i>Nature Genet.</i> , 1995 , 11, 219-222	
	7	Doan et al., "Protein Topology of Presenilin 1," <i>Neuron</i> , 1996 , 17, 1023-1030	
	8	Dower et al., "High efficiency transformation of <i>E.coli</i> by high voltage electroporation," <i>Nucl. Acids Res.</i> , 1988 , 16(13), 6127-6145	
	9	Duff et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <i>Nature</i> , 1996 , 383, 710-713	
	10	Fiering et al., "An "in-out" strategy using gene targeting and FLP recombinase for the functional dissection of complex DNA regulatory elements: Analysis of the β -globin locus control region," <i>Proc. Natl. Acad. Sci. USA</i> , 1993 , 90, 8469-8473	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004	Group Not Yet Assigned	
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Gu et al., "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting," <i>Science</i> , 1994 , 265, 103-106	
	12	Gu et al., "Independent Control of Immunoglobulin Switch Recombination at Individual Switch Regions Evidenced through Cre- <i>IoxP</i> -Mediated Gene Targeting," <i>Cell</i> , 1993 , 73, 1155-1164	
	13	Haass, "Presenilins: Genes for Life and Death," <i>Neuron</i> , 1997 , 18, 687-690	
*	14	Hogan et al., in <i>Manipulating the Mouse Embryo: A Laboratory Manual</i> , Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986	
	15	Holmes et al., "A Rapid Boiling Method for the Preparation of Bacterial Plasmids," <i>Anal. Biochem.</i> , 1981 , 114, 193-197	
	16	Kim et al., "Endoproteolytic Cleavage and Proteasomal Degradation of Presenilin 2 in Transfected Cells," <i>J. Biol. Chem.</i> , 1997 , 272(17), 11006-11010	
	17	Koller et al., "Altering Genes in Animals by Gene Targeting," <i>Ann. Rev. Immunol.</i> , 1992 , 10, 705-730	
	18	Kovacs et al., "Alzheimer-associated presenilins 1 and 2: Neuronal expression in brain and localization to intracellular membranes in mammalian cells," <i>Nature Med.</i> , 1996 , 2(2), 224-229	
	19	Lee et al., "Hyperaccumulation of FAD-linked presenilin 1 variants <i>in vivo</i> ," <i>Nature Med.</i> , 1997 , 3(7), 756-760	
	20	Levitan et al., "Assessment of normal and mutant human presenilin function in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 1996 , 93, 14940-14944	
EXAMINER			DATE CONSIDERED

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CEPH-2456/CP184B	Application No. 10/797,289
		Applicant Richard W. Scott	
		Filing Date march 10, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	Levitan et al., "Facilitation of <i>lin-12</i> -mediated signalling by <i>sel-12</i> , a <i>Caenorhabditis elegans</i> <i>S182</i> Alzheimer's disease gene," <i>Nature</i> , 1995 , 377, 351-354	
	22	Levy-Lahad et al., "Candidate Gene for the Chromosome 1 Familial Alzheimer's Disease Locus," <i>Science</i> , 1995 , 269, 973-977	
*	23	Maniatis et al., <i>Molecular Cloning - A Laboratory Manual</i> , 2nd edition, Cold Spring Harbor Press, 1989	
	24	Mullis et al., "[21] Specific Synthesis of DNA <i>in vitro</i> via a Polymerase-Catalyzed Chain Reaction," <i>Methods Enzymol.</i> , 1987 , 155, 335-350	
	25	Nagy et al., "Derivation of completely cell culture-derived mice from early-passage embryonic stem cells," <i>Proc. Natl. Acad. Sci.</i> , 1993 , 90, 8424-8428	
	26	Reaume et al., "Cardiac Malformation in Neonatal Mice Lacking Connexin43," <i>Science</i> , 1995 , 267, 1831-1834	
	27	Rogaev et al., "Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene," <i>Nature</i> , 1995 , 376, 775-778	
	28	Rubinstein et al., "Introduction of a point mutation into the mouse genome by homologous recombination in embryonic stem cells using a replacement type vector with a selectable marker," <i>Nucl. Acid Res.</i> , 1993 , 21(11), 2613-2617	
	29	Salehi et al., "Decreased Activity of Hippocampal Neurons in Alzheimer's Disease Is Not Related to the Presence of Neurofibrillary Tangles," <i>J. Neuropath. Exp. Neurol.</i> , 1995 , 54(5), 704-709	
	30	Sanger et al., "DNA sequencing with chain-terminating inhibitors," <i>Proc. Natl. Acad. Sci.</i> , 1977 , 74(12), 5463-5467	
EXAMINER		DATE CONSIDERED	

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	31	Scheuner et al., "Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased <i>in vivo</i> by the presenilin 1 and 2 and <i>APP</i> mutations linked to familial Alzheimer's disease," <i>Nature Med.</i> , 1996 , 2(8), 864-870	
	32	Sherrington et al., "Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease," <i>Nature</i> , 1995 , 375, 754-760	
	33	Siman et al., "Strategies to alter the progression of Alzheimer's disease," <i>Curr. Opin. Biotech.</i> , 1996 , 7, 601-607	
	34	Slunt et al., "Nucleotide sequence of the chromosome 14-encoded <i>SI82</i> cDNA and revised secondary structure prediction," <i>Amyloid - Int. J. Exp. Clin. Invest.</i> , 1995 , 2, 188-190	
	35	te Riele et al., "Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs," <i>Proc. Natl. Acad. Sci. USA</i> , 1992 , 89, 5128-5132	
	36	Thinakaran et al., "Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives in Vivo," <i>Neuron</i> , 1996 , 17, 181-190	
	37	Tybulewicz et al., "Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of the <i>c-abl</i> Proto-Oncogene," <i>Cell</i> , 1991 , 65, 1153-1163	
	38	Wang et al., "Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer's disease," <i>Nature Med.</i> , 1996 , 2(8), 871-875	
	39	Wasco et al., "Familial Alzheimer's chromosome 14 mutations," <i>Nature Med.</i> , 1995 , 1(9), 848	
	40	Wong et al., "Presenilin 1 is required for <i>Notch1</i> and <i>DIII</i> expression in the paraxial mesoderm," <i>Nature</i> , 1997 , 387, 288-292	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	41	Wood et al., "Non-injection methods for the production of embryonic stem cell-embryo chimaeras," <i>Nature</i> , 1993 , 365, 87-89	
	42	Wurst et al., "Production of targeted embryonic stem cell clones," in <i>Gene Targeting: A Practical Approach</i> , Joyner, A.L. (ed.), IRL Press, Oxford University Press, Oxford, England, 1993 , Ch. 2, 33-61	
	43	Ardis, <i>Society for Neurosc. Abstracts</i> , 2001 , 27(2), page 2344	
	44	Bishop, Chromosomal Insertion of Foreign DNA, 1996 , 607-619	
	45	Ebert, K.M., "A moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig," <i>Molecular Endocrinology</i> , 1988 , 2, 277-283	
	46	Ganten <i>Biomedical and Health Res.</i> , 1998 , 450-457	
	47	Hammer, R.E., et al., "Genetic engineering of mamalian embryos," <i>J. Animal Science</i> , 1986 , 63, 269-278	
	48	Koike, K., et al., "Expression of hepatitis C virus envelope proteins in transgenic mice," <i>J. Gen. Virology</i> , 1995 , 76, 3031-3038	
	49	Lee, M.K., et al., "Expression and endoproteolytic processing of wild type and FAD-linked mutant presenilin 1 in transgenic mice," <i>Molecular Biology of the Cell</i> 7 (Supplement), 1996 , 653A	
	50	Loring, <i>Neurobiology of Aging</i> , 1996 , 17(2), 173-182	
EXAMINER			DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	51	Palmiter, et al., <i>Ann Rev. Genet</i> , 1986 , 20, 465-499	
	52	Palmiter, et al., <i>PNAS</i> , 1991 , 88, 478-482	
	53	Polejaeva, et al., New Advances in Somatic Cell Nuclear Transfer: Application in Transgenesis, 2000 , 117-126	
	54	Rulicke, et al., Special Review Series-Gene Manipulation and Integrative Physiology, 1996 , 590-601	
	55	Wasco, W., et al., "Familial alzheimer's chromosome 14 mutations," <i>Nat. Med.</i> , 1995 , 1(9), 848	
	56	Wall, <i>Theriogenology</i> , 1996 , 43, 57-68	
	57	Whitelaw, et al., <i>Transgenic Res.</i> , 1991 , 1, 3-13	
	58	Aldudo, J., et al., "DGGE method for the mutational analysis of the coding and proximal promoter regions of the alzheimer's disease presenilin-1 gene: two novel mutations," <i>Human Mutat.</i> , 1999 , 14, 433-439	
	58	Aldudo, J., et al., "Identification of a novel mutation (Leu282Arg) of the human presenilin 1 gene in alzheimer's disease," <i>Neurosci. Lett.</i> , 1998 , 240, 174-176	
	60	Besancon, R., et al., "Missense mutation in exon 11 (Codon 378) of the presenilin-1 gene in a French family with early-onset alzheimer's disease and transmission study by mismatch enhanced allele specific amplification," <i>Human Mutat.</i> , 1998 , 11, 481 (abstract only)	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B	Application No. 10/797,289
	Applicant • Richard W. Scott	
	Filing Date March 10, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	61	Borchelt, D.R., et al., "Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins," <i>Neuron</i> , 1997 , 19, 939-945
	62	Campion, D., et al., Early-onset autosomal dominant alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum," <i>Am. J. Human Genet.</i> , 1999 , 65, 664-670
	63	Campion, D., et al., "Mutations of the presenilin 1 gene in families with early-onset alzheimer's disease," <i>Hum. Molec. Genet.</i> , 1995 , 4(12), 2373-2377
	64	Chui, D., et al., "Transgenic mice with alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation," <i>Nature Med.</i> , 1999 , 5(5), 560-564
	65	Citron, M., et al., "Mutant presenilins of alzheimer's disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice," <i>Nature Med.</i> , 1997 , 3(1), 67-72
	66	Cruts, M., et al., "Presenilin mutations in alzheimer's disease," <i>Human Mutat.</i> , 1998 , 11, 183-190
	67	De Strooper, B., et al., "Phosphorylation, subcellular localization, and membrane orientation of the alzheimer's disease-associated presenilins," <i>J. Biol. Chem.</i> , 1997 , 272(6), 3590-3598
	68	De Strooper, B., et al., "Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein," <i>Nature</i> , 1998 , 391, 387-390
	69	DeJonghe, C., et al., "Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile alzheimer's disease by increased A β 42 secretion," <i>Hum. Molec. Genet.</i> , 1999 , 8(8), 1529-1540
	70	Dumanchin, C., et al., "De novo presenilin 1 mutations are rare in clinically sporadic, early onset alzheimer's disease cases," <i>J. Med. Genet.</i> , 1998 , 35, 672-673
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	71	Ezquerra, M., et al., "A presenilin 1 mutation (Ser169Pro) associated with early-onset AD and myoclonic seizures," <i>Neurol.</i> , 1999 , 52, 566-570	
	72	Ezquerra, M., et al., "A novel presenilin 1 mutation (Leu166Arg) associated with early-onset alzheimer disease," <i>Arch. Neurol.</i> , 2000 , 57, 485-488	
	73	Flood, D.G., et al., "FAD mutant PS-1 gene-targeted mice: Increased A β 42 and A β deposition without APP overproduction," <i>Neurobiology of Aging</i> , 2002 , 23, 335-348	
	74	Gómez-Isla, T., et al., "A novel presenilin-1 mutation: increased β -amyloid and neurofibrillary changes," <i>Annals of Neurol.</i> , 1997 , 41(6), 809-813	
	75	Guo, Q., et al., "Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice," <i>Nature Med.</i> , 1999 , 5(1), 101-106	
	76	Hardy, J., "Amyloid, the presenilins and alzheimer's disease," <i>Trends Neurosci.</i> , 1997 , 20(4), 154-159	
	77	Hendriks, L., et al., "Processing of presenilin 1 in brains of patients with alzheimer's disease and controls," <i>NeuroReport</i> , 1997 , 8(7), 1717-1721	
	78	Holcomb, L., et al., "Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant <i>amyloid</i> precursor protein and <i>presenilin 1</i> transgenes," <i>Nature Med.</i> , 1998 , 4(1), 97-100	
	79	Hsiao, K., et al., "Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice," <i>Science</i> , 1996 , 274, 99-102	
	80	Kamimura, K., et al., Familial alzheimer's disease genes in Japanese," <i>J. Neurol. Sci.</i> , 1998 , 160, 76-81	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CEPH-2456/CP184B	Application No. 10/797,289
		Applicant Richard W. Scott	
		Filing Date March 10, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	81	Kowalska, A., et al., "A Polish pedigree with alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization," <i>Folia Neuropath.</i> , 1999 , 37(1), 57-61	
	82	Lamb, B.T., et al., "Amyloid production and deposition in mutant <i>amyloid</i> precursor protein and <i>presenilin-1</i> yeast artificial chromosome transgenic mice," <i>Nature Neurosci.</i> , 1999 , 2(8), 695-697	
	83	Lemere, C., et al., "The E280A presenilin 1 alzheimer mutation produces increased A β 42 deposition and severe cerebellar pathology," <i>Nature Med.</i> , 1996 , 2(10), 1146-1150	
	84	Lévesque, L., et al., "Developmental expression of wild-type and mutant presenilin-1 in hippocampal neurons from transgenic mice: evidence for novel species-specific properties of human presenilin-1," <i>Molec. Med.</i> , 1999 , 5, 542-554	
	85	Levey, A.I., et al., "Presenilin-1 protein expression in familial and sporadic alzheimer's disease," <i>Annals of Neurol.</i> , 1997 , 41(6), 742-753	
	86	Mann, D.M.A., et al., "Amyloid β protein (A β) deposition in chromosome 14-linked alzheimer's disease: predominance of A β 42(43)," <i>Annals of Neurol.</i> , 1996 , 40(2), 149-156	
	87	Mercken, M., et al., "Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: evidence that alzheimer mutations affect proteolytic processing," <i>FEBS Lett.</i> , 1996 , 389, 297-303	
	88	Murayama, O., et al., "Different effects of alzheimer-associated mutations of presenilin 1 on its processing," <i>Neurosci. Lett.</i> , 1997 , 229, 61-64	
	89	Murayama, O., et al., "Enhancement of amyloid β 42 secretion by 28 different presenilin 1 mutations of familial alzheimer's disease," <i>Neurosci. Lett.</i> , 1999 , 265, 61-63	
	90	Murayama, O., et al., "Twenty-nine missense mutations linked with familial alzheimer's disease alter the processing of presenilin 1," <i>Neuro-Psychopharmacol. Biol. Psychiatr.</i> , 1999 , 23, 905-913	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B	Application No. 10/797,289
	Applicant Richard W. Scott	
	Filing Date March 10, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	91	Nakano, Y., et al., "Accumulation of murine amyloid β 42, in a gene-dosage-dependent manner in PS1 'knock-in' mice," <i>Europ. J. Neuroscience</i> , 1999 , <i>11</i> , 2577-2581
	92	PCT International Search Report dated July 29, 2002 (PCT/US01/22693)
	93	Perez-Tur, J., et al., "A mutation in alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene," <i>NeuroReport</i> , 1995 , <i>7</i> , 297-301
	94	Podlisny, M.B., et al., "Presenilin proteins undergo heterogeneous endoproteolysis between thr ₂₉₁ and ala ₂₉₉ and occur a stable – and C- terminal fragments in normal and alzheimer brain tissue," <i>Neurobiol. Dis.</i> , 1997 , <i>3</i> , 325-337
	95	Prihar, G., et al., "Alzheimer disease PS-1 exon 9 deletion defined," <i>Nature Med.</i> , 1999 , <i>5(10)</i> , 1090
	96	Qian, S., et al., "Mutant human presenilin 1 protects <i>presenilin</i> 1 null mouse against embryonic lethality and elevates A β 1-42/43 expression," <i>Neuron</i> , 1998 , <i>20</i> , 611-617
	97	Reaume, A.G., et al., "Enhanced amyloidogenic processing of the β -amyloid precursor protein in gene-targeted mice bearing the swedish familial alzheimer's disease mutations and a "humanized" A β sequence," <i>J. Biol. Chem.</i> , 1996 , <i>271(38)</i> , 23380-23388
	98	Romero, I., et al., "A presenilin-1 thr116asn substitution in a family with early-onset alzheimer's disease," <i>NeuroReport</i> , 1999 , <i>10(11)</i> , 2255-2260
	99	Sato, S., et al., "Splicing mutation of presenilin-1 gene for early-onset familial alzheimer's disease," <i>Hum. Mutat. Suppl.</i> , 1998 , <i>1</i> , S91-94
	100	Sauer, B., et al., "Targeted insertion of exogenous DNA into the eukaryotic genome by the cre recombinase," <i>New Biol.</i> , 1990 , <i>2(5)</i> , 441-449
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289	
	Applicant Richard W. Scott			
	Filing Date March 10, 2004		Group Not Yet Assigned	
	Confirmation No. Not Yet Assigned			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	101	Savage, M.J., et al., "Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the β -amyloid precursor protein," <i>Neurosci.</i> , 1994 , 60(3), 607-619		
	102	Savage, M.J., et al., "Turnover of amyloid β -protein in mouse brain and acute reduction of its level by phorbol ester," <i>J. Neurosci.</i> , 1998 , 18(5), 1743-1752		
	103	Savage, M. J., et al, "Presenilin-1 P2641, Knock-in Mutation: Effect on Cortical Neuronal Vulnerability to Degeneration," <i>Dept. Pharmacology, Univ. Penna. School of Medicine, et al</i> , P.D. October 23, 1999 , XP-001089602, 1 page (Abstract)		
	104	Shen, J., et al., "Skeletal and CNS defects in presenilin-1-deficient mice," <i>Cell</i> , 1997 , 89, 629-639		
	105	Smith, M.J., et al., "Early-onset alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene," <i>NeuroReport</i> , 1999 , 10, 503-507		
	106	St. George-Hyslop, P.H., "Molecular genetics of alzheimer's disease," <i>Biol. Psychiatr.</i> , 2000 , 47, 183-199		
	107	Taddei, K., et al., "Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset alzheimer's disease," <i>NeuroReport</i> , 1998 , 9(14), 3335-3339		
	108	Takahashi, H., et al., "Impaired proteolytic processing of presenilin-1 in chromosome 14-linked familial alzheimer's disease patient lymphocytes," <i>Neurosci. Lett.</i> , 1999 , 260, 121-124		
	109	Theuns, J., et al., "Genetic variability in the regulatory region of presenilin 1 associated with risk for alzheimer's disease and variable expression," <i>Human Molec. Genet.</i> , 2000 , 9(3), 325-331		
	110	Vanderhoeven, I., et al., "proteolytic processing of presenilin-1 in human lymphoblasts is not affected by the presence of the I143T and G384A mutations," <i>Neurosci. Lett.</i> , 1999 , 274, 183-186		
EXAMINER		DATE CONSIDERED		

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/CP184B		Application No. 10/797,289
	Applicant Richard W. Scott		
	Filing Date March 10, 2004		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	111	Weibel, E.R. (ed.), "Practical methods for biological morphometry," <i>Stereological Methods</i> , 1979, 1, Academic Press, London	
	112	Yasuda, M., et al., "Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy," <i>J. Neurol. Neurosurg. Psychiatr.</i> , 2000, 68, 220-223	
	113	Yasuda, M., et al., "A pedigree with a novel presenilin 1 mutation at a residue that is not conserved in presenilin 2," <i>ARCH Neurol</i> , 1999, 56, 65-69	
	114	Yasuda, M., et al., "A novel missense mutation in the presenilin-1 gene in a familial alzheimer's disease pedigree with abundant amyloid angiopathy," <i>Neuroscience Letts.</i> , 1997, 232, 29-32	
	115	Siman, R., et al., "Presenilin-1 P264L knock-in mutation: effect on cortical neuronal vulnerability to degeneration," <i>Dept. Pharmac., Univ. Penn. School of Med., et al.</i> , 1999, page 1046	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CEPH-2456/ CP184B	Application No. 10/797,289
	Applicant Richard W. Scott	
	Filing Date March 10, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	116	4,959,317	09/25/90	Sauer	435	172.3
	117	5,777,194	07/07/98	Scott, et al.,	800	2
	118	5,850,003	12/1998	McLonlogue, et al.		
	119	5,877,399	03/02/99	Hsiao, et al.	800	2
	120	5,898,094	04/27/99	Duff et al	800	2
	121	5,986,054	11/16/99	St. George-Hyslop, et al.	530	350

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	122	WO 96/34097	10/31/96	PCT		
	123	WO 99/34670	07/15/99	PCT	X abstract	
	124	1 044 605 A1 English language equivalent of WO 99/34670	10/18/00	EPO		

EXAMINER	DATE CONSIDERED
-----------------	------------------------